Castle Biosciences completes acquisition of Cernostics for $30M upfront cash, up to $50M earnout

CASTLE BIOSCIENCES INC

Acquisition closed December 3, 2021; upfront cash consideration approximately $30 million.
Up to $50 million additional earnout payable in cash or stock upon achieving 2022 commercial milestones.
Merger agreement amended to cap stock issuance at 19.9% of outstanding shares for Nasdaq compliance.
Cernostics becomes wholly owned subsidiary; post-closing adjustments and escrow apply.
Financial statements of acquired business to be filed by amendment within 71 calendar days.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.